NO942363D0 - - Google Patents

Info

Publication number
NO942363D0
NO942363D0 NO942363A NO942363A NO942363D0 NO 942363 D0 NO942363 D0 NO 942363D0 NO 942363 A NO942363 A NO 942363A NO 942363 A NO942363 A NO 942363A NO 942363 D0 NO942363 D0 NO 942363D0
Authority
NO
Norway
Prior art keywords
triarylethylenes
aroylbenzothiophenes
phenylindoles
dihydronaphthalenes
benzopyrans
Prior art date
Application number
NO942363A
Other languages
English (en)
Other versions
NO312398B1 (no
NO942363L (no
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO942363D0 publication Critical patent/NO942363D0/no
Publication of NO942363L publication Critical patent/NO942363L/no
Publication of NO312398B1 publication Critical patent/NO312398B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
NO19942363A 1993-06-24 1994-06-21 2-fenyl-3-aroylbenzo[b]tiofener for reduksjon av blodglukosekonsentrasjoner NO312398B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8221893A 1993-06-24 1993-06-24

Publications (3)

Publication Number Publication Date
NO942363D0 true NO942363D0 (no) 1994-06-21
NO942363L NO942363L (no) 1994-12-27
NO312398B1 NO312398B1 (no) 2002-05-06

Family

ID=22169806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19942363A NO312398B1 (no) 1993-06-24 1994-06-21 2-fenyl-3-aroylbenzo[b]tiofener for reduksjon av blodglukosekonsentrasjoner

Country Status (23)

Country Link
US (1) US5567713A (no)
EP (1) EP0635264B1 (no)
JP (1) JP2886453B2 (no)
KR (1) KR100325034B1 (no)
CN (1) CN1086576C (no)
AT (1) ATE157869T1 (no)
AU (1) AU669627B2 (no)
CA (1) CA2126400A1 (no)
CZ (1) CZ285522B6 (no)
DE (1) DE69405491T2 (no)
DK (1) DK0635264T3 (no)
ES (1) ES2105525T3 (no)
GR (1) GR3025315T3 (no)
HU (1) HUT75253A (no)
IL (1) IL110052A (no)
NO (1) NO312398B1 (no)
NZ (1) NZ260790A (no)
PH (1) PH30490A (no)
PL (1) PL181025B1 (no)
RU (1) RU2132682C1 (no)
TW (1) TW275584B (no)
UA (1) UA34441C2 (no)
ZA (1) ZA944377B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6008377A (en) * 1996-03-19 1999-12-28 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxy-benzo[B]thiophenes
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN1390126B (zh) * 1999-07-06 2012-06-13 恩多研究公司 选择性雌激素受体调节剂在制备用于治疗或降低肥胖症发展危险性的药物中的用途
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
EP2455082A4 (en) * 2009-07-16 2012-12-19 Univ Kyushu Nat Univ Corp INSULIN-PRODUCING CELL INDUCER, GLUCOSE ABSORPTION ACTIVATOR AND THERAPEUTIC AGENT FOR DIABETES OR COMPLICATIONS OF DIABETES
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
WO2018027175A1 (en) * 2016-08-04 2018-02-08 University Of Iowa Research Foundation Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
BE637389A (no) * 1962-09-13
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4323707A (en) * 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE69023906T2 (de) * 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤

Also Published As

Publication number Publication date
DE69405491D1 (de) 1997-10-16
HU9401904D0 (en) 1994-09-28
AU669627B2 (en) 1996-06-13
US5567713A (en) 1996-10-22
ZA944377B (en) 1995-12-20
ATE157869T1 (de) 1997-09-15
KR950000145A (ko) 1995-01-03
CN1100933A (zh) 1995-04-05
DK0635264T3 (da) 1997-10-20
PH30490A (en) 1997-05-28
IL110052A0 (en) 1994-10-07
NO312398B1 (no) 2002-05-06
EP0635264A3 (en) 1995-04-12
CN1086576C (zh) 2002-06-26
NZ260790A (en) 1997-06-24
RU94022479A (ru) 1997-03-20
EP0635264B1 (en) 1997-09-10
PL181025B1 (pl) 2001-05-31
HUT75253A (en) 1997-05-28
JP2886453B2 (ja) 1999-04-26
TW275584B (no) 1996-05-11
NO942363L (no) 1994-12-27
EP0635264A2 (en) 1995-01-25
CA2126400A1 (en) 1994-12-25
KR100325034B1 (ko) 2002-08-21
CZ152094A3 (en) 1995-03-15
GR3025315T3 (en) 1998-02-27
IL110052A (en) 2001-04-30
RU2132682C1 (ru) 1999-07-10
AU6488294A (en) 1995-01-05
DE69405491T2 (de) 1998-02-19
JPH0748252A (ja) 1995-02-21
PL303937A1 (en) 1995-01-09
CZ285522B6 (cs) 1999-08-11
ES2105525T3 (es) 1997-10-16
UA34441C2 (uk) 2001-03-15

Similar Documents

Publication Publication Date Title
TW275584B (no)
HU9502193D0 (en) Combination treatment for inhibiting bone loss
PH30032A (en) Methods for inhibiting bone loss
AP9400635A0 (en) 1,5 Benzodiaze pine derivatives
CA2006267A1 (en) Method of treating herpesviruses
GB2359077B (en) Pushout mechanism for I.S. machine
GB2223404B (en) Inositoltrisphosphate for the treatment of abnormal levels of lipoproteins
HU9204076D0 (en) Method for producing 4,13-dioxa-bicyclo(8.2.1)-tridecenone derivatives
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
EP0657438A3 (en) Process for the preparation of alkylulfinylbenzamides and 1,2-benzoisothiazol-3-ones.
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
ZA892171B (en) 4-aryl-4-piperidine(or pyrrolidine or hexahydroazepine)carbinols and heterocyclic analogs thereof
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
EP0641533A3 (de) Sitz eines Operateurstuhles.
FR2631966B1 (no)
PL281255A1 (en) Method for manufacturing a new 3-(6,6-dimethylbicyclo (3.1.0) hextrans-3-yl) ethyl (prop-2)e) enate
PL281256A1 (en) Method for manufacturing a new 3-(6,6-dimethylbicyclo (3.1.0) hextrans-3-yl) ehtyl propanion
EP0796092A4 (en) DIMERES OF 3.3- (DISUBSTITUTED) CYCLOHEXAN-ONE AND RELATED COMPOUNDS

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees